Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma

  • STATUS
    Recruiting
  • End date
    Dec 30, 2025
  • participants needed
    150
  • sponsor
    Peking University
Send
Updated on 16 February 2024
See if I qualify

Summary

The optimal first-line treatment for extra-nodal NK/T-cell lymphoma (ENKTL) has not been well-defined. This phase II study aimed to evaluate the efficacy and safety of pegaspargase, cyclophosphamide, vincristine, etoposide and prednisone (COEPL) regimen combined with radiotherapy for patients with newly diagnosed ENKTL.

Details
Condition NK/T Cell Lymphoma Nos
Age 14years - 80years
Treatment pegaspargase, cyclophosphamide, vincristine, etoposide, prednisone
Clinical Study IdentifierNCT04484506
SponsorPeking University
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

patients with confirmed pathological diagnosis of ENKTL as defined by WHO criteria
age 14-80 years
no prior chemotherapy or radiotherapy
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
at least one measurable lesion
adequate bone marrow function (i.e. hemoglobin 80 g/l, absolute neutrophil count 1.0 10^9/L, platelets 100 10^9/L), adequate renal function (i.e. serum creatinine 177 mol/L), adequate hepatic function (e.g. total bilirubin two times the upper limit of normal, and ALT /AST 2.5 times the upper limit of normal)
expected survival of more than three months

Exclusion Criteria

invasion of lymphoma to central nervous system
pre-existing coagulation disorder
other concomitant neoplasms
severe infection
positive HIV antibody
HBV DNA titer higher than 10^4 copies /ml in HBsAg-positive patients post antiviral therapy
pregnant or lactating women
women of childbearing age unwilling to take contraceptive measures during the study period
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.